Abstract:Peptide inhibition of the interactions of the tumor suppressor protein P53 with its negative regulators MDM2 and MDMX activates P53 in vitro and in vivo, representing a viable therapeutic strategy for cancer treatment. Using phage display techniques, we previously identified a potent peptide activator of P53, termed PMI (TSFAEYWNLLSP), with binding affinities for both MDM2 and MDMX in the low nanomolar concentration range. Here we report an ultrahigh affinity, dual-specificity peptide antagonist of MDM2 and MDMX obtained through systematic mutational analysis and additivity-based molecular design. Functional assays of over 100 peptide analogs of PMI using surface plasmon resonance and fluorescence polarization techniques yielded a dodecameric peptide termed PMI-M3 (LTFLEYWAQLMQ) that bound to MDM2 and MDMX with Kd values in the low picomolar concentration range as verified by isothermal titration calorimetry. Co-crystal structures of MDM2 and of MDMX in complex with PMI-M3 were solved at 1.65 and 3.0 Å resolution, respectively. Similar to PMI, PMI-M3 occupied the P53-binding pocket of MDM2/MDMX, which was dominated energetically by intermolecular interactions involving Phe3, Tyr6, Trp7, and Leu10. Notable differences in binding between PMI-M3 and PMI were observed at other positions such as Leu4 and Met11 with MDM2, and Leu1 and Met11 with MDMX, collectively contributing to a significantly enhanced binding affinity of PMI-M3 for both proteins. By adding lysine residues to both ends of PMI and PMI-M3 to improve their cellular uptake, we obtained modified peptides termed PMI-2K (KTSFAEYWNLLSPK) and M3-2K (KLTFLEYWAQLMQK). Compared with PMI-2K, M3-2K exhibited significantly improved antitumor activities in vitro and in vivo in a P53-dependent manner. This super-strong peptide inhibitor of the P53-MDM2/MDMX interactions may become, in its own right, a powerful lead compound for anticancer drug development, and can aid molecular design of other classes of P53 activators as well for anticancer therapy.

Structural adaptation of secondary p53 binding sites on MDM2 and MDMX

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

Functional Interrogation of the N-Terminal Lid of MDMX in p53 Binding via Native Chemical Ligation.

Structural Basis for High-Affinity Peptide Inhibition of P53 Interactions with MDM2 and MDMX.

Modulation of the p53-MDM2 Interaction by Phosphorylation of Thr18: A Computational Study

Probing the origin of structural stability of single and double stapled p53 peptide analogs bound to MDM2

Small Molecule Inhibitors of the P53-Mdm2

Systematic Mutational Analysis of Peptide Inhibition of the P53-Mdm2/Mdmx Interactions

Kinetic and thermodynamic effects of phosphorylation on p53 binding to MDM2

Secondary Interaction Between MDMX and P53 Core Domain Inhibits P53 DNA Binding.

A computational analysis of interaction mechanisms of peptide and non-peptide inhibitors with MDMX based on molecular dynamics simulation

Interrogation of MDM2 Phosphorylation in P53 Activation Using Native Chemical Ligation: the Functional Role of Ser17 Phosphorylation in MDM2 Reexamined

Quantum Mechanical Studies of Residue-Specific Hydrophobic Interactions in P53-Mdm2 Binding.

The central region of HDM2 provides a second binding site for p53

P53 Alpha-Helix Mimetics Antagonize P53/mdm2 Interaction and Activate P53.

Transient Protein States in Designing Inhibitors of the MDM2-p53 Interaction

Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression

Insight Into Binding Modes Of P53 And Inhibitors To Mdm2 Based On Molecular Dynamic Simulations And Principal Component Analysis

Molecular Dynamics Simulations Studies and Free Energy Analysis on Inhibitors of Mdm2-P53 Interaction

Free Energy Profile and Kinetics of Coupled Folding and Binding of the Intrinsically Disordered Protein p53 with MDM2

P53 Α-Helix Mimetics Antagonize P53/mdm2 Interaction and Activate P53